Efficacy and safety of alpelisib plus olaparib versus chemotherapy among patients with platinum-resistant or refractory high-grade serous ovarian cancer without BRCA mutation: Primary analysis of the EPIK-O trial

Saved in:
Bibliographic Details
Published in:Gynecologic oncology 2024-11, Vol.190, p.S12-S12
Main Authors: Konstantinopoulos, Panagiotis, Kim, Jae-Weon, Freyer, Gilles, Lee, Jung-Yun, Gaba, Lydia, Grisham, Rachel, Colombo, Nicoletta, Wu, Xiaohua, Sehouli, Jalid, Cruz, Felipe, Cibula, David, Monk, Bradley, Nyvang, Gitte-Bettina, Friedlander, Michael, Lorusso, Domenica, Van Nieuwenhuysen, Els, Glasspool, Rosalind, Marth, Christian, Hinson, Patsy, Zuradelli, Monica, Wang, Craig, Su, Faye, Miller, Michelle, Matulonis, Ursula, González-Martín, Antonio
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0090-8258
DOI:10.1016/j.ygyno.2024.07.024